This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same information for proceedings before the Patent Trial and Appeal Board concerning Orange Book-listed patents.
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Celgene Corp. v. Mylan Pharms. Inc., 20-0003 (N.D.W.V.) | Jan. 3, 2020 | Hon. Irene M. Keeley | Revlimid® (lenalidomide capsules) | 7,189,740 7,465,800 7,855,217 7,968,569 8,404,717 8,530,498 8,648,095 9,056,120 9,101,621 9,101,622 |
| Exela Pharma Sciences, LLC v. Avadel Legacy Pharms., LLC, 20-0024 (D. Del.) | Jan. 7, 2020 | Hon. Maryellen Noreika | Elcys® (cysteine HCl for injection) Nouress™ (cysteine HCl for injection) | 10,478,453 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 20-0315 (D.N.J.) | Jan. 8, 2020 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 |
| Almirall, LLC v. Zydus Pharms. (USA) Inc., 20-0343 (D.N.J.) | Jan. 9, 2020 | Hon. Freda L. Wolfson | Aczone® (dapsone gel) | 9,517,219 |
| Almirall, LLC v. Mylan Pharms. Inc., 20-0006 (N.D.W.V.) | Jan. 9, 2020 | Hon. Irene M. Keeley | Aczone® (dapsone gel) | 9,517,219 |
| Amgen Inc. v. Torrent Pharma Inc., 20-0065 (D. Del.) | Jan. 16, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 20-0534 (D.N.J.) | Jan. 16, 2020 | Hon. Claire C. Cecchi | Dificid® (fidaxomicin tablets) | 7,906,489 8,586,551 7,378,508 7,863,249 8,859,510 |
| Novartis Pharms. Corp. v. Alembic Pharms. Ltd., 20-0074 (D. Del.) | Jan. 17, 2020 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Amgen Inc. v. Zydus Pharms. (USA) Inc., 20-0075 (D. Del.) | Jan. 17, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Merck Sharp & Dohme Corp. v. Actavis Labs. FL, Inc., 20-20217 (S.D. Fla.) | Jan. 17, 2020 | Hon. Ursula Ungaro | Dificid® (fidaxomicin tablets) | 7,906,489 8,586,551 7,378,508 7,863,249 8,859,510 |
| Vanda Pharms. Inc. v. Apotex Inc., 20-0083 (D. Del.) | Jan. 21, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Amgen Inc. v. Zydus Pharms. (USA) Inc., 20-0678 (D.N.J.) | Jan. 21, 2020 | Hon. Freda L. Wolfson | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 20-0093 (D. Del.) | Jan. 22, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Amgen Inc. v. Bionpharma, Inc., 20-0105 (D. Del.) | Jan. 23, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Relypsa, Inc. v. Alkem Labs. Ltd., 20-0106 (D. Del.) | Jan. 23, 2020 | Hon. Maryellen Noreika | Veltassa® (patiromer sorbitex calcium powder for oral suspension) | 8,337,824 9,492,476 9,925,212 |
| Merck Sharp & Dohme Corp. v. Sandoz Inc., 20-0783 (D.N.J.) | Jan. 23, 2020 | Hon. Brian R. Martinotti | Noxafil® (posaconazole oral suspension) | 8,263,600 |
| Janssen Products, L.P. v. Zydus Pharms. (USA) Inc., 20-0787 (D.N.J.) | Jan. 23, 2020 | Hon. Freda L. Wolfson | Prezista® (darunavir tablets) | 7,700,645 8,518,987 7,126,015 7,595,408 |
| Amgen Inc. v. Annora Pharma Private Ltd., 20-0122 (D. Del.) | Jan. 24, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Amgen Inc. v. Centaur Pharms. Private Ltd., 20-0123 (D. Del.) | Jan. 24, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Novartis Pharms. Corp. v. Apotex Inc., 20-0133 (D. Del.) | Jan. 28, 2020 | Hon. Leonard P. Stark | Gilenya® (fingolimod capsules) | 10,543,179 |
| Sucampo Gmbh v. Zydus Pharms. (USA) Inc., 20-0936 (D.N.J.) | Jan. 28, 2020 | Hon. Freda L. Wolfson | Amitiza® (lubiprostone capsules) | 7,795,312 8,026,393 8,338,639 8,779,187 8,748,481 |
| Amgen Inc. v. MSN Pharms., Inc., 20-0137 (D. Del.) | Jan. 29, 2020 | Hon. Colm F. Connolly | Corlanor® (ivabradine tablets) | 7,361,649 7,361,650 7,867,996 7,879,842 |
| Pfizer Inc. v. Viwit Pharm. Co., Ltd., 20-0160 (D. Del.) | Jan. 31, 2020 | Hon. Colm F. Connolly | Chantix® (varenicline tartrate tablets) | 6,410,550 6,890,927 7,265,119 |
| Silvergate Pharms., Inc. v. CMP Development LLC, 20-0161 (D. Del.) | Jan. 31, 2020 | Hon. Leonard P. Stark | Qbrelis® (Lisinopril oral solution) | 9,463,183 9,616,096 9,814,751 10,039,800 10,265,370 10,406,199 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00368 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 8,163,723 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00369 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 8,168,620 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00370 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 9,259,428 |
| GlaxoSmithKline Consumer Healthcare Holdings (US), LLC v. Cipla Ltd., IPR2020-00371 (PTAB) | Jan. 31, 2020 | N/A | Dymista® (azelastine HCl / fluticasone propionate metered spray) | 9,901,585 |
| Boehringer Ingelheim Pharms. Inc. v. Mylan Pharms. Inc., 20-0019 (N.D.W.V.) | Feb. 5, 2020 | Hon. Irene M. Keeley | Tradjenta® (linagliptin tablets) | 9,486,526 |
| Boehringer Ingelheim Pharms. Inc. v. Aurobindo Pharma Ltd., 20-0023 (N.D.W.V.) | Feb. 5, 2020 | Hon. John Preston Bailey | Tradjenta® (linagliptin tablets) | 9,486,526 |
| Gilead Sciences, Inc. v. Apotex, Inc., 20-0189 (D. Del.) | Feb. 7, 2020 | Hon. Maryellen Noreika | Vemlidy® (tenofovir alafenamide tablets) Descovy® (emtricitabine / tenofovir alafenamide tablets) Odefsey® (emtricitabine / rilpivirine / tenofovir alafenamide tablets) | 7,390,791 7,803,788 8,754,065 9,296,769 |
| American Regent, Inc. v. Pharmacosmos Therapeutics Inc., 20-1350 (D.N.J.) | Feb. 7, 2020 | Hon. Brian R. Martinotti | Monoferric® (ferric derisomaltose for injection) | 8,431,549 10,478,450 |
| Allergan Sales, LLC v. Breckenridge Pharm., Inc., 20-0199 (D. Del.) | Feb. 10, 2020 | Hon. Mitchell S. Goldberg | Saphris® (asenapine maleate sublingual tablets) | 5,763,476 |
| AstraZeneca AB v. Alembic Pharms. Ltd., 20-0202 (D. Del.) | Feb. 11, 2020 | Hon. Richard G. Andrews | Tagrisso® (osimertinib mesylate tablets) | 10,183,020 |
| Vifor (Int’l) AG v. Mylan Labs. Ltd., 20-1647 (D.N.J.) | Feb. 14, 2020 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 10,519,252 |
| Vifor (Int’l) AG v. Sandoz Inc., 20-1649 (D.N.J.) | Feb. 14, 2020 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 10,519,252 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 20-0235 (D. Del.) | Feb. 19, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,376,487 |
| Astellas US LLC v. Int’l Medication Systems, Ltd., 20-0273 (D. Del.) | Feb. 25, 2020 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8,106,183 RE47,301 8,524,883 |
| Boehringer Ingelheim Pharms. Inc. v. Annora Pharma Private Ltd., 20-0277 (D. Del.) | Feb. 25, 2020 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Millennium Pharms., Inc. v. Sun Pharm. Indus. Ltd., 20-0289 (D. Del.) | Feb. 27, 2020 | Hon. Colm F. Connolly | Ninlaro® (ixazomib citrate capsules) | 7,442,830 8,859,504 9,175,017 |
| ViiV Healthcare Co. v. Lupin Ltd., 20-0293 (D. Del.) | Feb. 28, 2020 | Hon. Mitchell S. Goldberg | Juluca® (dolutegravir sodium / rilpivirine HCl tablets) | 9,242,986 10,426,780 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-0300 (D. Del.) | Feb. 28, 2020 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib citrate tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-0301 (D. Del.) | Feb. 28, 2020 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-2222 (D.N.J.) | Feb. 28, 2020 | Hon. Freda L. Wolfson | Xeljanz XR® (tofacitinib extended-release tablets) | 6,965,027 7,301,023 RE41,783 |
| Pfizer Inc. v. Zydus Pharms. (USA) Inc., 20-2227 (D.N.J.) | Feb. 28, 2020 | Hon. Freda L. Wolfson | Xeljanz® (tofacitinib citrate tablets) | 6,965,027 7,301,023 RE41,783 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 20-0318 (D. Del.) | Mar. 3, 2020 | Hon. Colm F. Connolly | Hetlioz® (tasimelteon capsules) | 10,449,176 |
| Takeda Pharms. U.S.A., Inc. v. Alkem Labs. Ltd., 20-0325 (D. Del.) | Mar. 3, 2020 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets)) | 7,906,519 7,935,731 8,093,298 7,964,648 8,093,297 7,619,004 7,601,758 7,820,681 7,915,269 7,964,647 7,981,938 8,093,296 8,097,655 8,415,395 8,415,396 8,440,721 8,440,722 |
| Encore Dermatology Inc. v. Glenmark Pharms. Ltd., 20-2509 (D.N.J.) | Mar. 6, 2020 | Hon. Kevin McNulty | Impoyz® (clobetasol propionate cream) | 9,956,231 |
| Astellas US LLC v. Gland Pharma Ltd., 20-0347 (D. Del.) | Mar. 9, 2020 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8,106,183 RE47,301 8,524,883 |
| Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., 20-2576 (D.N.J.) | Mar. 10, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Celgene Corp. v. Apotex Inc., 20-2593 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Breckenridge Pharm., Inc., 20-2597 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Hetero Labs Ltd., 20-2601 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 20-2606 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 20-2607 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Mylan Pharms. Inc., 20-2608 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Celgene Corp. v. Teva Pharms. USA, Inc., 20-2614 (D.N.J.) | Mar. 10, 2020 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 10,555,939 |
| Bausch Health US, LLC v. Aleor Dermaceuticals Ltd., 20-2735 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Alkem Labs. Ltd., 20-2737 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Aurobindo Pharma USA Inc., 20-2738 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Amneal Pharms. LLC v. Cubist Pharms. LLC, IPR2020-00193 (PTAB) | Nov. 27, 2019 | N/A | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Bausch Health US, LLC v. KVK-Tech, Inc., 20-2742 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Lupin Ltd., 20-2744 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Strides Pharma Inc., 20-2746 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Taro Pharms. U.S.A., Inc., 20-2747 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Zydus Pharms. (USA) Inc., 20-2748 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Bausch Health US, LLC v. Mylan Pharms. Inc., 20-2749 (D.N.J.) | Mar. 12, 2020 | Hon. Brian R. Martinotti | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Merck Sharp & Dohme B.V. v. Gland Pharma Ltd., 20-2750 (D.N.J.) | Mar. 12, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Teva Pharms. USA, Inc., 20-2751 (D.N.J.) | Mar. 12, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Braintree Labs., Inc. v. Alkem Labs. Ltd., 20-0362 (D. Del.) | Mar. 13, 2020 | Hon. Colm F. Connolly | Suprep® Bowel Prep Kit (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Merck Sharp & Dohme B.V. v. Lupin Ltd., 20-2786 (D.N.J.) | Mar. 13, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Mankind Pharma Ltd., 20-2787 (D.N.J.) | Mar. 13, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 6,949,527 |
| Bausch Health US, LLC v. Mylan Pharms. Inc., 20-0046 (N.D.W.V.) | Mar. 13, 2020 | Hon. Irene M. Keeley | Jublia® (efinaconazole topical solution) | 10,512,640 10,342,875 10,478,601 |
| Exela Pharma Sciences, LLC v. Eton Pharms., Inc., 20-0365 (D. Del.) | Mar. 16, 2020 | Hon. Maryellen Noreika | Elcys® (cysteine HCl for injection) | 10,478,453 10,583,155 |
| Merck Sharp & Dohme B.V. v. Fresenius Kabi USA, LLC, 20-2892 (D.N.J.) | Mar. 16, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Braintree Labs., Inc. v. Alkem Labs. Ltd., 20-2904 (D.N.J.) | Mar. 16, 2020 | Hon. Peter G. Sheridan | Suprep® Bowel Prep Kit (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Merck Sharp & Dohme B.V. v. Dr. Reddy’s Labs., Inc., 20-2909 (D.N.J.) | Mar. 16, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Fisiopharma S.R.L., 20-2964 (D.N.J.) | Mar. 17, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. Sun Pharm. Indus., Inc., 20-3007 (D.N.J.) | Mar. 18, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Hoffmann-La Roche, Inc. v. Fresenius Kabi USA, LLC, 20-0394 (D. Del.) | 19-Mar-20 | Hon. Richard G. Andrews | Alcensa® (alectinib HCl capsules) | 9,126,931 9,440,922 9,365,514 10,350,214 |
| Merck Sharp & Dohme B.V. v. Zydus Pharms. (USA) Inc., 20-3068 (D.N.J.) | Mar. 19, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Merck Sharp & Dohme B.V. v. USV Private Ltd., 20-3072 (D.N.J.) | Mar. 19, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Pharmacyclics LLC v. Sun Pharma Global FZE, 20-0403 (D. Del.) | Mar. 20, 2020 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib tablets) | 10,478,439 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc. 20-3102 (D.N.J.) | Mar. 20, 2020 | Hon. Renee Marie Bumb | Invokamet XR® (canagliflozin / metformain HCl extended-release tablets) | 7,943,582 8,513,202 |
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA, Inc. 20-3106 (D.N.J.) | Mar. 20, 2020 | Hon. Freda L. Wolfson | Invokamet XR® (canagliflozin / metformain HCl extended-release tablets) | 7,943,788 8,222,219 8,785,403 |
| Merck Sharp & Dohme B.V. v. Aspiro Pharma Ltd., 20-3112 (D.N.J.) | Mar. 20, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 6,949,527 |
| Merck Sharp & Dohme B.V. v. Sandoz Inc., 20-3117 (D.N.J.) | Mar. 20, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Cubist Pharms. LLC v. Mylan Pharms Inc., 20-3168 (D.N.J.) | Mar. 23, 2020 | Hon. Brian R. Martinotti | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Novartis Pharms. Corp. v. Lupin Atlantis Holdings, S.A., 20-0415 (D. Del.) | Mar. 24, 2020 | Hon. Leonard P. Stark | Entresto® (sacubitril / valsartan tablets) | 8,101,659 8,796,331 8,877,938 9,388,134 |
| Cubist Pharms. LLC v. Mylan Pharms. Inc., 20-0052 (N.D.W.V.) | Mar. 24, 2020 | Hon. Irene M. Keeley | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 20-3229 (D.N.J.) | Mar. 25, 2020 | Hon. Michael A. Shipp | Sprycel® (dasatinib tablets) | 7,491,725 |
| Merck Sharp & Dohme B.V. v. Mylan API US LLC, 20-3270 (D.N.J.) | Mar. 25, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Salix Pharms., Ltd. v. Norwich Pharms., Inc., 20-0430 (D. Del.) | Mar. 26, 2020 | Hon. Richard G. Andrews | Xifaxan® (rifaximin tablets) | 7,045,620 7,612,199 7,902,206 7,906,542 7,915,275 8,158,644 8,158,781 8,193,196 8,309,569 8,518,949 8,642,573 8,741,904 8,829,017 8,835,452 8,853,231 8,946,252 8,969,398 9,271,968 9,421,195 9,629,828 10,314,828 10,335,397 10,456,384 |
| Ferring Pharms. Inc. v. Fresenius Kabi USA, LLC, 20-0431 (D. Del.) | Mar. 26, 2020 | Hon. Maryellen Noreika | Firmagon® (degarelix for injection) | 9,579,359 9,415,085 8,841,081 9,877,999 8,828,938 |
| Merck Sharp & Dohme B.V. v. MSN Labs. Private Ltd., 20-3314 (D.N.J.) | Mar. 26, 2020 | Hon. Claire C. Cecchi | Bridion® (sugammadex for injection) | RE44,733 |
| Mallinckrodt Hospital Products IP Ltd. v. Baxter Healthcare Corp., 20-0434 (D. Del.) | Mar. 27, 2020 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) | 9,399,012 9,610,265 9,987,238 10,383,834 6,992,218 |
Related Attorneys
Partner
